Multiplexing Phenotype and Function for More Biologically Relevant Insights - 26

Related Article from

When Success Rates Go Low, Cell-Based Screens Go High
To Boost Success Rates, Developers are Balancing High-Content and High-Throughput Screening
Richard A. A. Stein M.D., Ph.D.

O

ver the past 10 years, the costs of developing a new therapeutic drug, from
research and development to marketing approval, has more than doubled.
Yet only about 1 in 1000 compounds progresses from preclinical studies
to human testing. Many compounds identified from large screens fail during
clinical trials, typically during Phase II, motivating drug developers to reconsider
their screening strategies. For example, many developers are looking for ways to
implement high-content screening while maintaining acceptably high levels of
throughput.
"If we look at drug discovery over the past three decades, one conclusion, for both
small molecules and proteins, is that we have been overly simplistic in the way
we identify early drug candidates," says Jean-Philippe Stephan, Ph.D., director of
the Center of Excellence for Pharmacological Screening, Compound Management
and Biobanking, Institut de Recherches Servier. A key effort in Dr. Stephan's group
focuses on identifying, early during the research phase, chemical compounds that
have the potential to be developed into therapeutic agents.
"As part of this work, we made investments in platforms to perform high-content
screening," reveals Dr. Stephan. Drug discovery efforts at Servier focus on therapeutic areas that include oncology, metabolism, immuno-inflammation, neurobiology, and cardiovascular diseases.
Balancing Content and Throughput
"For a long time, we thought that drug discovery was just a matter of numbers,
and that if we looked for a needle in a haystack and screened as many compounds
as possible, we would end up finding that needle-even if we used a simple
screening method," relates Dr. Stephan. This view encouraged the development of
large chemical libraries, containing millions of compounds, that could be interrogated to identify drugs of interest.
26

| January, 2019

In a recent study that discussed the sustainability
of current drug discovery approaches, Dr. Stephan
and colleagues highlighted the key benefits and
challenges of high-content analysis for phenotypic
drug discovery.


http://www.genengnews.com

Multiplexing Phenotype and Function for More Biologically Relevant Insights

Table of Contents for the Digital Edition of Multiplexing Phenotype and Function for More Biologically Relevant Insights

Contents
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 1
Multiplexing Phenotype and Function for More Biologically Relevant Insights - Contents
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 3
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 4
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 5
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 6
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 7
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 8
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 9
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 10
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 11
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 12
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 13
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 14
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 15
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 16
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 17
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 18
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 19
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 20
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 21
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 22
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 23
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 24
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 25
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 26
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 27
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 28
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 29
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 30
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 31
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 32
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 33
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 34
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 35
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 36
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 37
Multiplexing Phenotype and Function for More Biologically Relevant Insights - 38
https://www.nxtbookmedia.com